대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	It is time to consider individualized treatment goal for anemia in ESRD
저자	Shin Young Ahn, Min-ho Kim, Yoo Jeong Kim, Jong Ah Lo, Jin Sun Kim, Eunjeong Cho, Gang Jee Ko, Young Joo Kwon
출판정보	2019; 2019(1):
키워드	hemoglobin \| anemia \| hemodialysis \| mortality \| hospitalization
초록	We investigated an allowable upper limit of hemoglobin (hgb) level for ESA therapy in ESRD using Korean Society of Nephrology (KSN) ESRD registry. We review the data from KSN ESRD registry between January 2010 and December 2017. Among 78,409 hemodialysis patients registered, we enrolled the patients who were 19 years or older, measured serum hgb twice or more, and were followed up clinically for more than 12 months. Finally, 26,910 patients were analyzed and their mean follow-up duration was 4.78 ± 2.14 years. During the follow-up period, 3,133 (11.6%) patients died and 11,132 (41.4%) patients admitted to hospital. The patients were assigned to the six groups according to their initial Hgb levels: group 1 < 8, 8 ≤ group 2 < 9, 9 ≤ group 3 < 10, 10 ≤ group 4 < 11, 11 ≤ group 5 < 12, group 6 ≥ 12 g/dL. Those with higher hgb level were more likely to be young and men, to have higher levels of albumin, calcium, phosphorous, and uric acid. They also tended to use lesser amount of erythropoiesis-stimulating agents (ESAs). After multiple logistic regression of variables related to hospitalization, we found that group 6 had lower risk for hospitalization in patients with following characteristics: male, chronic glomerulonephritis, 1 ≤ dialysis vintage < 5 years, and dialysis vintage ≥ 10 years. Regarding mortality, we demonstrated similar results after multiple cox regression analysis. Although there were several limitations associated with retrospective study, we observed that higher hgb levels would be beneficial in certain patients.
원문(PDF)	PDF 원문보기

목록

위로가기